keyword
MENU ▼
Read by QxMD icon Read
search

interim Pet hodgkin

keyword
https://www.readbyqxmd.com/read/27913497/response-adapted-frontline-therapy-for-hodgkin-lymphoma-are-we-there-yet
#1
Peter W M Johnson
Treating Hodgkin lymphoma by using chemotherapy with or without radiotherapy is highly successful, with substantially fewer deaths from lymphoma than from other causes in recent studies of both early-stage and advanced-stage disease. Long-term toxicity is a major consideration in this context, and recent trials have used functional imaging with [(18)F]fluorodeoxyglucose (FDG) positron emission tomography early in the course of treatment (interim PET) to assess response and modulate subsequent therapy. In early-stage disease, this has allowed omission of consolidation radiotherapy after a good response to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy, and trials have shown that this can be done without detriment to overall survival, despite a small increase in rates of recurrence of ∼5%...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27879369/standardized-response-assessment-criteria-and-their-applications-in-lymphoma-part-2
#2
Mateen Collis Moghbel, Erik Mittra, Andrea Gallamini, Ryan Niederkohr, Delphine Chen, Katherine Zukotynski, Helen Nadel, Lale Kostakoglu
Interim and end-of-treatment PET/CT have become central to the evaluation of Hodgkin's and non-Hodgkin's lymphoma. This review article seeks to aid clinical decision-making by providing an overview of available data on the diagnostic and prognostic value of PET/CT imaging for response assessment and pre-transplant evaluation in lymphoma. The relative strengths and limitations of these techniques in various disease subtypes and clinical scenarios are explored, along with their current standards for reporting and latest developments...
November 22, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27867987/modifying-therapy-in-patients-with-advanced-hodgkin-s-lymphoma-by-integrating-early-metabolic-response-by-interim-pet-ct
#3
EDITORIAL
Ulrike Bacher, Mascha Binder
No abstract text is available yet for this article.
October 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27795508/update-on-the-use-of-fdg-pet-ct-in-malignant-lymphoma
#4
Takashi Terauchi
This article aims to explain the current status of FDG-PET/CT in malignant lymphoma management by reviewing the new recommendations for evaluation, staging, and response assessment in patients with malignant lymphoma, published as the Lugano Classification in 2014. FDG-PET/CT was formally incorporated into standard staging for FDG-avid lymphoma in this new classification. Nearly all subtypes of malignant lymphoma are FDG-avid. In staging, the increased FDG uptake compatible with lymphoma is considered to represent involvement of lymphoma, regardless of size, and the FDG-avid lesion is potentially a good biopsy target...
2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/27776647/proportion-of-false-positive-lesions-at-interim-and-end-of-treatment-fdg-pet-in-lymphoma-as-determined-by-histology-systematic-review-and-meta-analysis
#5
Hugo J A Adams, Thomas C Kwee
PURPOSE: To systematically review and meta-analyze the proportion of false-positive lesions at interim and end-of-treatment (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in lymphoma using biopsy as reference standard. MATERIALS AND METHODS: Medline was searched for original studies. Methodological quality of included studies was evaluated, and results were meta-analytically summarized using random effects (in case of interstudy heterogeneity [I(2)≤50%]) or fixed effects (in case of no interstudy heterogeneity [I(2)>50%])...
November 2016: European Journal of Radiology
https://www.readbyqxmd.com/read/27754902/post-treatment-pet-ct-rather-than-interim-pet-ct-using-deauville-criteria-predicts-outcome-in-pediatric-hodgkin-lymphoma-a-prospective-study-comparing-pet-ct-versus-conventional-imaging
#6
Sameer Bakhshi, Sainath Bhethanabhotla, Rakesh Kumar, Krishankant Agarwal, Punit Sharma, Sanjay Thulkar, Arun Malhotra, Deepa Dhawan, Sreenivas Vishnubhatla
BACKGROUND: Data about significance of (18)F-FDG positron emission tomography (PET) at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. METHODS: Patients (≤18 years) with HL were prospectively evaluated with contrast-enhanced computed tomography (CECT) and PET combined with low-dose CT(PET-CT) at baseline, post 2 cycles of chemotherapy and post completion of treatment. Revised international working group criteria (RIW) and Deauville (DA) five point-scale for response assessment by PET-CT were used...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27693134/interim-pet-scans-in-diffuse-large-b-cell-lymphoma-is-it-ready-for-prime-time
#7
REVIEW
Maital Bolshinsky, Chadi Nabhan
Prognostication of patients with diffuse large B-cell lymphoma (DLBCL) has improved in the past decade with a variety of clinical, morphologic, molecular, and radiographic methods. Comparable to data on the value of interim positron emission tomography (I-PET) in Hodgkin lymphoma, several retrospective and prospective studies are attempting to assess the value of I-PET scanning in DLBCL patients. In this review, we briefly describe and analyze the various prognostic methods in DLBCL with specific focus on the value of I-PET scanning in this disease...
December 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27692305/the-combined-role-of-biomarkers-and-interim-pet-scan-in-prediction-of-treatment-outcome-in-classical-hodgkin-s-lymphoma-a-retrospective-european-multicentre-cohort-study
#8
Claudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, Patrizia Agati, Claudio Tripodo, Fabio Fuligni, Maria Teresa Sista, Stefano Fanti, Alberto Biggi, Umberto Vitolo, Luigi Rigacci, Francesco Merli, Caterina Patti, Alessandra Romano, Alessandro Levis, Livio Trentin, Caterina Stelitano, Anna Borra, Pier Paolo Piccaluga, Stephen Hamilton-Dutoit, Peter Kamper, Jan Maciej Zaucha, Bogdan Małkowski, Waldemar Kulikowski, Joanna Tajer, Edyta Subocz, Justyna Rybka, Christian Steidl, Alessandro Broccoli, Lisa Argnani, Randy D Gascoyne, Francesco d'Amore, Pier Luigi Zinzani, Stefano A Pileri
BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease. METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to Dec 31, 2012...
October 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27692302/high-risk-interim-pet-negative-patients-in-hodgkin-s-lymphoma
#9
Michel Meignan
No abstract text is available yet for this article.
October 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27539369/hodgkin-lymphoma-a-negative-interim-pet-cannot-circumvent-the-need-for-end-of-treatment-pet-evaluation
#10
Charles Mesguich, Anne-Laure Cazeau, Krimo Bouabdallah, Pierre Soubeyran, Martine Guyot, Noël Milpied, Laurence Bordenave, Elif Hindié
We examined the outcome of a cohort of patients with Hodgkin lymphoma (HL) in order to assess if fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) at the end of treatment (end-PET) can be omitted when the interim PET (int-PET) is negative. Seventy-six ABVD(adriamycin, bleomycin, vinblastine, dacarbazine)-treated patients were retrospectively included. No change in treatment was made on the basis of int-PET results. Suspicious foci on end-PET received biopsy confirmation whenever possible...
November 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27531807/-recent-advances-on-treatment-of-hodgkin-s-lymphoma-review
#11
Yan-Fen Li, Hai-Yan Zhu
Outstanding progress has been achieved in the treatment of Hodgkin's lymphoma in recent years, most of patients can be cured by using modern therapy. However, more and more attentions have been paid on treatment-related complications, the current treatment strategies are focusing on further improving treatment efficacy, while reducing treatment-related toxicity. It is still to be determined whether interim PET imaging could directly judge the therapeutic response so as to make the individualized treatment programs for the patients, for instance through intensifying or abbreviating chemotherapy regimens and/or omitting radiotherapy...
August 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/27528557/controversies-on-the-prognostic-value-of-interim-fdg-pet-in-advanced-stage-hodgkin-lymphoma
#12
REVIEW
Hugo J A Adams, Thomas C Kwee
Hodgkin lymphoma, even in advanced-stage, is a highly curable malignancy, but treatment is associated with short-term toxicity and long-term side effects. Early predictive markers are required to identify those patients who do not require the full-length standard therapy (and thus qualify for therapy de-escalation) and those patients who will not be cured by standard therapy (and thus qualify for therapy escalation). Multiple trials have assessed the value of (18) F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) after a few cycles of chemotherapy (also known as 'interim FDG-PET') in predicting outcome in advanced-stage Hodgkin lymphoma...
December 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27501435/does-interim-18f-fdg-pet-response-adapted-therapy-really-benefit-advanced-stage-hodgkin-lymphoma-patients
#13
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
August 5, 2016: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27496308/treatment-of-advanced-stage-hodgkin-lymphoma
#14
REVIEW
Theodoros P Vassilakopoulos, Peter W M Johnson
There is now good evidence that the escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) is more effective in controlling advanced-stage Hodgkin lymphoma (HL) than the widely used ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine), but the extra efficacy comes at the expense of both short- and long-term toxicity, and there is debate as to whether overall survival is affected. Baseline prognostic factors have proven of limited utility for determining which patients require more intensive therapy and recent studies have sought to use interim fluoro-deoxyglucose positron emission tomography (FDG-PET) evaluation as a means to guide the modulation of treatment, both upwards and downwards in intensity...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496236/comparing-the-accuracy-of-quantitative-versus-qualitative-analyses-of-interim-pet-to-prognosticate-hodgkin-lymphoma-a-systematic-review-protocol-of-diagnostic-test-accuracy
#15
Vít Procházka, Miloslav Klugar, Veronika Bachanova, Jitka Klugarová, Dagmar Tučková, Tomáš Papajík
INTRODUCTION: Hodgkin lymphoma is an effectively treated malignancy, yet 20% of patients relapse or are refractory to front-line treatments with potentially fatal outcomes. Early detection of poor treatment responders is crucial for appropriate application of tailored treatment strategies. Tumour metabolic imaging of Hodgkin lymphoma using visual (qualitative) 18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a gold standard for staging and final outcome assessment, but results gathered during the interim period are less accurate...
2016: BMJ Open
https://www.readbyqxmd.com/read/27455136/current-developments-in-the-treatment-of-early-stage-classical-hodgkin-lymphoma
#16
Sven Borchmann, Bastian von Tresckow, Andreas Engert
PURPOSE OF REVIEW: After presenting the current treatment recommendations for early-stage Hodgkin lymphoma, we give an overview on recently published clinical trials in this setting. Furthermore, the potential influence of current trials on the treatment of early-stage Hodgkin lymphoma and integration of newly emerging drugs into treatment protocols will be discussed. RECENT FINDINGS: Trials attempting treatment de-escalation and omission of radiotherapy on the basis of early interim PET-scans have been disappointing so far, but results of some large trials employing this strategy are still awaited...
September 2016: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27386786/feasibility-of-interim-positron-emission-tomography-pet-adapted-therapy-in-hiv-positive-patients-with-advanced-hodgkin-lymphoma-hl-a-sub-analysis-of-swog-s0816-phase-2-trial
#17
Alexey V Danilov, Hongli Li, Oliver W Press, Ilan Shapira, Lode J Swinnen, Ariela Noy, Erin Reid, Sonali M Smith, Jonathan W Friedberg
No abstract text is available yet for this article.
February 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27380902/ct-based-texture-analysis-potentially-provides-prognostic-information-complementary-to-interim-fdg-pet-for-patients-with-hodgkin-s-and-aggressive-non-hodgkin-s-lymphomas
#18
B Ganeshan, K A Miles, S Babikir, R Shortman, A Afaq, K M Ardeshna, A M Groves, I Kayani
OBJECTIVES: The purpose of this study was to investigate the ability of computed tomography texture analysis (CTTA) to provide additional prognostic information in patients with Hodgkin's lymphoma (HL) and high-grade non-Hodgkin's lymphoma (NHL). METHODS: This retrospective, pilot-study approved by the IRB comprised 45 lymphoma patients undergoing routine 18F-FDG-PET-CT. Progression-free survival (PFS) was determined from clinical follow-up (mean-duration: 40 months; range: 10-62 months)...
July 5, 2016: European Radiology
https://www.readbyqxmd.com/read/27332902/adapted-treatment-guided-by-interim-pet-ct-scan-in-advanced-hodgkin-s-lymphoma
#19
RANDOMIZED CONTROLLED TRIAL
Peter Johnson, Massimo Federico, Amy Kirkwood, Alexander Fosså, Leanne Berkahn, Angelo Carella, Francesco d'Amore, Gunilla Enblad, Antonella Franceschetto, Michael Fulham, Stefano Luminari, Michael O'Doherty, Pip Patrick, Thomas Roberts, Gamal Sidra, Lindsey Stevens, Paul Smith, Judith Trotman, Zaid Viney, John Radford, Sally Barrington
BACKGROUND: We tested interim positron-emission tomography-computed tomography (PET-CT) as a measure of early response to chemotherapy in order to guide treatment for patients with advanced Hodgkin's lymphoma. METHODS: Patients with newly diagnosed advanced classic Hodgkin's lymphoma underwent a baseline PET-CT scan, received two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy, and then underwent an interim PET-CT scan. Images were centrally reviewed with the use of a 5-point scale for PET findings...
June 23, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27281359/interim-fluorine-18-fluorodeoxyglucose-pet-computed-tomography-and-cell-of-origin-by-immunohistochemistry-predicts-progression-free-and-overall-survival-in-diffuse-large-b-cell-lymphoma-patients-in-the-rituximab-era
#20
Renata de Oliveira Costa, Abrahão Hallack Neto, Sheila Siqueira, Luis Alberto de Padua Covas Lage, Henrique M de Paula, Arthur M Coutinho, Juliana Pereira
OBJECTIVE: The aim of this study was to analyze the prognostic value of the interim PET (iPET)-computed tomography (CT) (iPET-CT) after two cycles of immunochemotherapy with the R-CHOP protocol in patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) treated with a curative intent in combination with the neoplastic cell origin defined by Hans's immunohistochemstry algorithm followed in a reference center for cancer treatment in Brazil. MATERIALS AND METHODS: We prospectively evaluated 147 DLBCL patients treated with R-CHOP-21 to assess the value of the International Prognostic Index, iPET-CT, and cell of origin by immunohistochemistry as prognostic markers in the rituximab era...
October 2016: Nuclear Medicine Communications
keyword
keyword
118763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"